Fosamax FDA Approval History: Everything You Need to Know About Alendronate's Regulatory Record

When Was Fosamax First FDA Approved?

Fosamax (alendronate sodium) was approved by the FDA on September 29, 1995, under NDA 019-993, for treatment of osteoporosis in postmenopausal women. That single approval anchored Merck's osteoporosis franchise for the next decade and established alendronate as the reference bisphosphonate against which all later drugs in the class were compared.

The original 10 mg once-daily tablet was the only formulation. The 70 mg once-weekly tablet, which dramatically improved adherence rates in real-world practice, did not arrive until 2000.

The Pre-Approval Trial Package

The FDA's 1995 review rested primarily on two-year randomized controlled data showing alendronate 10 mg/day increased lumbar spine BMD by approximately 8.8% compared with placebo, with statistically significant reductions in radiographic vertebral fractures. These data came from studies that would later be consolidated into the broader FIT program.

The Fracture Intervention Trial (FIT), published in JAMA in 1998 [1], enrolled 2,027 women aged 55 to 81 with low femoral neck BMD. Alendronate reduced the risk of hip fracture by 51% (RR 0.49, 95% CI 0.23 to 0.99) and reduced clinical vertebral fractures by 55% over three years. This remains the most cited fracture-endpoint trial supporting alendronate's label.

Regulatory Pathway and NDA Number

Alendronate was reviewed under a standard NDA, not a priority review. The NDA number 019-993 is publicly accessible through Drugs@FDA. Prescribers and pharmacists can download every historical label version, approval letter, and review document from that page.

How Has the Fosamax Label Expanded Over Time?

The label has gone through seven major revisions covering new indications, new dosage forms, new safety communications, and generic approval milestones. Each expansion reflects either new clinical-trial data submitted by Merck or FDA-initiated safety actions based on post-market surveillance [2].

1997: Prevention of Postmenopausal Osteoporosis

Two years after the treatment indication, FDA approved the 5 mg once-daily dose for prevention of osteoporosis in postmenopausal women not yet meeting the BMD threshold for treatment. This was a significant market extension because it targeted a much larger population of women in early menopause.

1999: Glucocorticoid-Induced Osteoporosis

Long-term corticosteroid use causes bone loss in up to 50% of patients within the first year of therapy [3]. The 1999 label expansion added glucocorticoid-induced osteoporosis (GIOP) as an indication, supported by 48-week randomized data showing alendronate 5 mg and 10 mg significantly increased lumbar spine BMD compared with placebo in patients receiving at least 7.5 mg/day prednisone-equivalent. The American College of Rheumatology's 2022 GIOP guidelines continue to recommend bisphosphonates as first-line therapy for high-risk patients [4].

2000: Male Osteoporosis and the 70 mg Weekly Tablet

Two label changes landed in 2000. First, FDA approved alendronate 10 mg once daily for treatment of osteoporosis in men, based on a two-year multicenter trial (N=241) showing 7.1% lumbar spine BMD gain versus 1.8% with placebo. Second, the 70 mg once-weekly formulation received approval. A 12-month head-to-head study (N=1,258) demonstrated non-inferiority of weekly 70 mg versus daily 10 mg on lumbar spine BMD change, with a similar adverse-event profile [5].

Weekly dosing nearly doubled one-year adherence rates in subsequent observational studies, a finding that has direct implications for fracture outcomes because adherence below 80% significantly attenuates BMD benefit [6].

2008: First Generic Approval

Barr Pharmaceuticals received the first generic alendronate approval in February 2008. The FDA's generic approval required bioequivalence demonstration under 21 CFR Part 320. Multiple additional ANDA approvals followed rapidly, collapsing Fosamax's branded market share from above 80% to below 20% within 18 months.

What Are the Key Fosamax Label Safety Warnings?

The current Prescribing Information for alendronate contains warnings that have accumulated through a combination of spontaneous adverse-event reports submitted to FDA's MedWatch system, post-market studies, and Sentinel network analyses [7].

Esophageal Reactions (1996 Safety Communication)

Within one year of the 1995 approval, Merck and FDA received reports of esophagitis, esophageal ulcers, and esophageal erosions in patients taking alendronate. A 1996 label update added explicit instructions requiring patients to take the tablet with a full 6 to 8 oz glass of plain water, remain upright for at least 30 minutes, and not take the tablet at bedtime or before rising. These instructions remain on the current label verbatim.

Patients with active upper GI disease, Barrett's esophagus, or inability to stand or sit upright for 30 minutes are contraindicated or require careful evaluation before prescribing [8].

Osteonecrosis of the Jaw (ONJ, 2005)

In September 2004 and through 2005, FDA received accumulating case reports linking bisphosphonate use to osteonecrosis of the jaw, predominantly in oncology patients receiving high-dose intravenous bisphosphonates, but also in patients taking oral bisphosphonates for osteoporosis [9]. The 2005 label update added a warnings section describing ONJ, characterizing it as exposed bone in the maxillofacial region that failed to heal within eight weeks.

The American Association of Oral and Maxillofacial Surgeons defines medication-related osteonecrosis of the jaw (MRONJ) as "necrotic bone in the maxillofacial region in a patient with current or previous treatment with antiresorptive agents, with no history of radiation therapy to the jaw and no metastatic disease to the jaw" [10].

Incidence in patients taking oral bisphosphonates for osteoporosis is estimated at 0.001% to 0.01% per year, substantially lower than the 1% to 15% rate seen with intravenous bisphosphonates in oncology [9].

Atypical Femoral Fractures (2010)

This safety update is the most discussed of all post-market actions on alendronate. In October 2010, FDA required label changes across all bisphosphonates, including alendronate, to include a new warnings and precautions section on atypical subtrochanteric and diaphyseal femoral fractures [11].

The clinical picture is distinctive: a prodromal aching or dull thigh pain precedes a low-energy or atraumatic fracture of the femoral shaft, often bilateral, with a transverse or short oblique fracture pattern on imaging. A case-series analysis in the New England Journal of Medicine described 310 atypical femoral fractures, of which 94% occurred in bisphosphonate users [12].

The absolute risk remains low. Among women taking alendronate, the background rate of subtrochanteric fracture is approximately 2 per 100,000 person-years; bisphosphonate use may increase this to roughly 50 per 100,000 person-years after prolonged exposure, still far below the fracture risk reduction benefit in high-risk patients [13].

Hypocalcemia Warning

Alendronate, like all bisphosphonates, can worsen pre-existing hypocalcemia. The label requires correction of hypocalcemia before initiating therapy. Patients with vitamin D deficiency are at particular risk, and co-prescribing calcium and vitamin D supplementation is standard practice per both the label and the Endocrine Society's osteoporosis guidelines [14].

Musculoskeletal Pain (2008 Safety Communication)

FDA issued a safety communication in January 2008 noting that bisphosphonates, including alendronate, may cause severe and sometimes incapacitating bone, joint, or muscle pain. This communication followed review of 112 cases submitted to MedWatch between 1995 and 2006. Pain onset ranged from one day to several years after starting therapy; symptoms resolved in most patients who discontinued treatment [15].

What Does the Current Fosamax Prescribing Information Specify?

The current FDA-approved Prescribing Information for alendronate (referenced from the most recent label on Drugs@FDA) covers the following key prescribing parameters [8].

Approved Indications and Doses

| Indication | Dose | |---|---| | Treatment of postmenopausal osteoporosis | 10 mg once daily OR 70 mg once weekly | | Prevention of postmenopausal osteoporosis | 5 mg once daily OR 35 mg once weekly | | Glucocorticoid-induced osteoporosis (men and women) | 5 mg once daily (10 mg once daily for postmenopausal women not on estrogen) | | Treatment of osteoporosis in men | 10 mg once daily OR 70 mg once weekly | | Paget's disease of bone | 40 mg once daily for 6 months |

Renal Dosing Restrictions

Alendronate is contraindicated in patients with creatinine clearance below 35 mL/min. Renal impairment at this threshold significantly prolongs skeletal retention of the drug and increases the theoretical risk of adverse effects, though direct clinical trial data in severe CKD are limited [8].

Drug Interactions

Calcium supplements, antacids, and many oral medications reduce alendronate absorption when co-administered. The label requires that alendronate be taken at least 30 minutes before the first food, beverage other than plain water, or other oral medication. Aspirin and NSAIDs increase upper GI adverse-event risk, warranting caution in patients already on these agents [8].

How Has FDA Monitored Alendronate Post-Market?

Post-market surveillance for alendronate has used three primary mechanisms: MedWatch spontaneous reporting, the FDA Sentinel System, and congressionally mandated safety reviews [16].

FDA Sentinel Network Analyses

The FDA Sentinel System, which links electronic health data from over 100 million patients, has been used to quantify atypical femur fracture rates, esophageal cancer risk, and cardiovascular signals associated with bisphosphonate use [16]. A 2012 Sentinel analysis found no statistically significant association between oral bisphosphonate use and esophageal cancer, contradicting earlier case-report signals and a 2010 BMJ study that had raised concern [17].

The HORIZON Key Fracture Trial Context

Although HORIZON was conducted with zoledronic acid rather than alendronate, its 2007 NEJM publication (N=7,765, 3-year fracture data) is routinely used by FDA reviewers as class-level context when evaluating bisphosphonate safety signals [18]. The trial showed zoledronic acid reduced hip fracture risk by 41% and clinical vertebral fracture risk by 77%, reinforcing the class benefit-risk profile at the time of FDA's 2010 atypical fracture communication.

Drug Holiday Guidance

No FDA-approved label currently specifies a "drug holiday" duration. The 2022 American Society for Bone and Mineral Research (ASBMR) task force report recommends reassessing fracture risk after three to five years of oral bisphosphonate therapy and considering a treatment break of one to two years in lower-risk patients who have achieved stable BMD [19]. This guidance appears in clinical practice guidelines rather than the FDA label itself.

Alendronate Generic Market: What FDA Approved and When

The generic field for alendronate is extensive. The first ANDA approval in 2008 opened the market; as of 2025, more than 25 generic versions have received FDA approval [2]. All generics must demonstrate bioequivalence to the reference listed drug (Fosamax) under FDA's Orange Book standards.

Orange Book Listing

Alendronate sodium tablets are listed in the FDA Orange Book under therapeutic equivalence code AB, meaning substitution by pharmacists is permitted in all U.S. States absent specific prescriber instructions [2]. The 70 mg/75 mL oral solution (brand: Binosto effervescent tablet, not the solution) carries a separate NDA.

Biosimilar Considerations

Alendronate is a small-molecule drug, not a biologic, so the biosimilar framework does not apply. All generics are evaluated under the standard ANDA pathway with bioequivalence requirements, not the more complex 351(k) pathway used for biologics [2].

Clinical Implications: What the Regulatory Record Means for Prescribers

Reading the regulatory history of alendronate as a clinical document reveals several practice-relevant conclusions that are easy to miss when relying only on summary guidelines.

Benefit-Risk Remains Favorable for High-Risk Patients

The FIT trial (N=2,027, JAMA 1998 [1]) demonstrated a number needed to treat of approximately 20 over three years to prevent one hip fracture in women with existing vertebral fractures and low BMD. In women with osteopenia alone, NNT rises substantially, which is why prevention-dose labeling (5 mg) exists as a separate indication rather than using treatment doses across the board.

The Endocrine Society's 2019 Pharmacological Management of Osteoporosis guideline states: "For women with postmenopausal osteoporosis at high risk for fracture, we recommend pharmacological treatment to reduce fracture risk" and identifies bisphosphonates as first-line agents given their fracture-efficacy data, long safety record, and low cost [14].

Duration of Therapy Remains an Open Regulatory Question

FDA has not approved any label language specifying optimal treatment duration or holiday protocols. The 2011 FLEX trial extension (N=1,099) showed that women who continued alendronate for 10 years had a lower rate of clinical vertebral fractures compared with those who stopped at five years (2.4% vs. 5.3%, P<0.001), but did not show significant differences in non-vertebral fracture rates [20]. This trial is cited in guidelines but not incorporated into FDA-approved label language.

Monitoring Recommendations

The label does not mandate specific BMD monitoring intervals. The National Osteoporosis Foundation and Endocrine Society both recommend repeat DXA scanning every one to two years when initiating therapy, with intervals extending to every two to three years once stable response is established [14]. Serum calcium, phosphate, and renal function should be checked before initiating therapy and periodically during treatment in patients at risk for metabolic bone disturbances.

The current Prescribing Information remains the authoritative source for dosing and safety, accessible through the FDA Drugs@FDA portal under NDA 019-993. Clinicians managing patients on long-term alendronate should review the most recent label before counseling on fracture risk, treatment duration, and atypical fracture symptoms.